Ponvory (ponesimod)
- Region
- 🇪🇺 EU
- Active substance
- ponesimod
- Company
- Laboratoires Juvisé Pharmaceuticals
- Status
- Authorised
- Therapeutic area
- Multiple Sclerosis, Relapsing-Remitting
- CHMP opinion
- Thu 25 Mar 2021
- EU approval
- Wed 19 May 2021
- Application
- EMEA/H/C/005163
- ATC
- L04AE04
- Official record
- www.ema.europa.eu
Indication
Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.
Regulatory milestones
No milestones recorded in the last year.
Follow Ponvory
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.